In a post hoc analysis, assessment of TP53 mutation status showed that women with TP53 mutant EC had both improved progression free- and overall survival when treated with bevacizumab and chemotherapy, whereas women with TP53 wild-type tumours showed no difference in outcomes.63 The authors concluded p53/TP53 could be used as a biomarker to help predict patients with EC more likely to respond to bevacizumab treatment. Here, TP53 is linked to neoplasm.